MBX Biosciences, Inc. Common Stock
$30.05
-2.1%MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -12.6).
Valuation inputs: P/E -12.6, earnings yield N/A, momentum -2.1%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -23.6%, ROIC -26.5%).
Profitability stack: net margin 0.0%, ROE -23.6%, ROIC -26.5%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +4.1%, momentum -2.1%, net margin 0.0%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
MBX Biosciences, Inc. Common Stock Market vs Earnings Trajectory
Loading price and EPS data...
MBX Biosciences, Inc. Common Stock Fair Value Envelope
No Revenue Data
MBX has not reported any revenue values in the available annual periods.
MBX Biosciences, Inc. Common Stock Profit Bridge
Profitability Analysis
No Gross Profit Margin Data
MBX has not reported any gross profit margin values in the available annual periods.
No Operating Profit Margin Data
MBX has not reported any operating profit margin values in the available annual periods.
No Net Profit Margin Data
MBX has not reported any net profit margin values in the available annual periods.
MBX Biosciences, Inc. Common Stock Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
MBX Biosciences, Inc. Common Stock Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
MBX Biosciences, Inc. Common Stock Street Expectations Map
Wall Street analysts project that MBX stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 60.33, with estimates ranging from a low of 18.00 to a high of 88.00.
The consensus 1-year price target stands at 60.33, with estimates ranging from a low of 18.00 to a high of 88.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
High uncertainty. Very wide target spread indicates significant disagreement among analysts—major valuation uncertainty or transformation underway.
Risk-Reward Profile
Favorable risk-reward. Potential upside significantly exceeds downside risk, offering asymmetric return profile attractive for risk-tolerant investors.
Analyst Conviction
High uncertainty: Wide dispersion indicates analysts struggle to agree on valuation—proceed with caution and independent analysis.
Market Sentiment Insight
High risk, high reward: Substantial upside potential exists, but wide analyst disagreement signals execution risk or unclear catalysts. Thorough due diligence essential before committing capital.
MBX Biosciences, Inc. Common Stock Insider Positioning
During the last 12 months, insiders have purchased $16.13M and sold $2.14M worth of MBX shares, resulting in $14.00M of net buying activity.
3 Months
18.5K
525.66K
55.8K
2.14M
-1.6M
-$1.61M
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
989.5K
15.61M
0
0.00
+15.6M
+$15.61M
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
Heron Patrick J
Director, 10 Percent Owner:
$12.00M
Hoerter Steven L.
Director
$2.74M
Hawryluk P. Kent
Director, Officer: President & Ceo
$1.39M
Top Sellers
Azoulay Salomon
Officer: Chief Medical Officer
$2.12M
Hawryluk P. Kent
Director, Officer: President & Ceo
$18K
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $14.00M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
3 insider buyers vs. 2 sellers. More insiders buying than selling indicates positive sentiment.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
No Dividend Yield Data
MBX has not reported any dividend yield values in the available annual periods.
mbx Dividend History
Learning Layer
Related Guides
Build conviction on MBX by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.